Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381642 | 1.00 | EGFR (1.00) | EGFR | |
| SCHEMBL22821733 | 0.97 | EGFR (0.95) | EGFR | |
| SCHEMBL22821945 | 0.95 | EGFR (0.91) | EGFR | |
| SCHEMBL22026202 | 0.94 | EGFR (0.88) | EGFR | |
| SCHEMBL22025587 | 0.94 | EGFR (0.88) | EGFR | |
| SCHEMBL23065821 | 0.93 | EGFR (0.88) | EGFR | |
| SCHEMBL30459972 | 0.93 | EGFR (0.88) | EGFR | |
| SCHEMBL22595300 | 0.93 | EGFR (0.87) | EGFR | |
| SCHEMBL22822110 | 0.93 | EGFR (0.87) | EGFR | |
| SCHEMBL22821851 | 0.93 | EGFR (1.00) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-3656769-B1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-20220119431-A1 | SALT OF EGFR INHIBITOR, CRYSTAL FORM, AND PREPARATION METHOD THEREFOR | MEDSHINE DISCOVERY INC. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3912976-A1 | SALT OF EGFR INHIBITOR, CRYSTAL FORM, AND PREPARATION METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021018009-A1 | EGFR INHIBITOR, COMPOSITION, AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-02-04 | — | — | WO | disclosed |
| WO-2020216371-A1 | EGFR INHIBITOR AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2020-10-29 | — | — | WO | disclosed |
| WO-2020200191-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020147838-A1 | SALT OF EGFR INHIBITOR, CRYSTAL FORM, AND PREPARATION METHOD THEREFOR | 正大天晴药业集团股份有限公司 | 2020-07-23 | — | — | WO | disclosed |
| US-20200207768-A1 | Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| EP-3656769-A1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119431-A1 | SALT OF EGFR INHIBITOR, CRYSTAL FORM, AND PREPARATION METHOD THEREFOR | EGFR, WEE1, WEE2 | EGFR 1/4885 |
| US-20200207768-A1 | Aryl-Phosphorus-Oxygen Compound As EGFR Kinase Inhibitor | EGFR, ERBB2, ERBB3 | EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.